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Previews(mainly PDE4), resulting in increased
cAMP levels and stimulation of a Ca2+-
dependent pathway involving CamKKb
(Park et al., 2012). Some groups suggest
that SIRT1 functions much later in the
pathway, after AMPK stimulates NAD+
production through increased transcrip-
tion of NAD+ synthetic enzymes (Um
et al., 2010). Regardless of the proposed
mechanism, the transcriptional coactiva-
tor PGC1a is the ultimate recipient of the
signaling pathway. Using C2C12 cells,
Price et al. showed that lower doses of
resveratrol increased SIRT1-dependent
phosphorylation of AMPK, while a higher
dose led to SIRT1-independent activation
of AMPK. Interestingly, the two doses dis-
played opposite trends; higher resveratrol
decreased NAD+ and ATP levels, while
the lower dose led to increases in both
metabolites, though the NAD+ change
was not evident until 12 hr. These results
convincingly demonstrate that different
dosages of resveratrol can elicit varied
responses.
Most importantly, the work by Price
et al. provides strong evidence that
SIRT1 is a critical player in mediating the
effects of resveratrol on mitochondrial
biogenesis and the switch to more oxida-
tive muscle fibers (Price et al., 2012).
Given the pleiotropic effects of resvera-
trol, the molecular mechanism remainsin dispute. When and how are SIRT1 and
PDE4 involved in the resveratrol-depen-
dent activation of AMPK? How does
resveratrol concentration differentially
affect the reported targets and their asso-
ciated signaling pathways? A careful time
course analysis of all the implicated
factors is essential. For example, if
SIRT1 is directly activated by resveratrol,
then upon treatment, deacetylation of
LKB1 should precede or coincide with
AMPK phosphorylation. Similarly, does
SIRT1-dependent deacetylation of
PGC1a occur prior to, coincident with,
or after initial AMPK activation? It will be
important to dissect the initial signaling
events from those of the metabolically
reprogrammed state. Increased NAD+
synthesis might to be a long-term adap-
tion to drive sustained sirtuin function or
to replenish NAD+ levels as a result of an
initial surge in sirtuin activity. The results
from Price et al. strengthen the biological
link between resveratrol and SIRT1-
dependent processes, and provide a
backdrop to further studies that resolve
the mechanism.REFERENCES
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Impaired activity of peroxisome proliferator-activated receptor (PPAR)-g coactivator (PGC)-1a has been
implicated in the pathophysiology of several neurodegenerative disorders. In this issue, Da Cruz et al.
(2012) show improvedmuscle function, but not survival, with increased PGC-1a activity in muscle in amouse
model of amyotrophic lateral sclerosis.Amyotrophic lateral sclerosis (ALS) is a
progressive neurodegenerative disease
that targets motor neurons in the brainand spinal cord, resulting in muscle weak-
ness, atrophy, and eventual death. In
about 20% of familial ALS cases, thedisease is associated with mutations
in the gene that encodes copper-zinc
superoxide dismutase (SOD1), whichm 15, May 2, 2012 ª2012 Elsevier Inc. 567
Figure 1. Improving Muscle Function Alone Is Not Sufficient to Combat ALS
(A) PGC-1a normally binds to the nuclear receptors (NR), such as the nuclear respiratory factor-1 (NRF-1), and modulates the expression of genes involved in
mitochondrial biogenesis and function (right panel). The SOD1 mutant mice have reduced activity of PGC-1a, as well as mitochondrial dysfunction and muscle
atrophy (left panel). Previous studies proposed that ALS originates in muscle, and from there it spreads to axons through neuromuscular junctions—and that in
ALS neuronal death is a secondary consequence of degeneration of muscle starting from neuromuscular junctions.
(B) Da Cruz et al. (2012) now disprove the speculation that muscle alone is responsible for neuronal death in ALS. Increasing PGC-1a activity in muscle in amouse
model of ALS caused by a SOD1mutation results in increasedmitochondrial biogenesis, reducedmuscle atrophy, and improved strength and performance. Total
area ofmitochondria permyofiberwas significantly increased by 3- to 4-fold (right panel). IncreasedPGC-1a activity improvesmuscle strength throughout illness;
however, it does not extend survival (left panel). This study shows that improving PGC-1a activity in muscle is an attractive palliative therapy for ALS.
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Previewsaggregates and causes mitochondrial
dysfunction.
Da Cruz et al. (2012) show that increas-
ing peroxisome proliferator-activated
receptor (PPAR)-g coactivator-1a (PGC-
1a) activity in muscle in a transgenic
mouse model of ALS caused by a muta-
tion in SOD1 is able to sustain muscle
function throughout the disease course;
however, survival was not extended.
This surprising result directly addresses
a controversy that has arisen in the field
of ALS research, which was whether the
expression of mutant SOD1 in muscle
alone is sufficient to cause the illness
(Figure 1A). Prior work showed that
muscle-restricted expression of mutant
SOD1 in mice produced muscle damage568 Cell Metabolism 15, May 2, 2012 ª2012and atrophy (Dobrowolny et al., 2008;
Wong and Martin, 2010) and in one study
caused degeneration of motor neurons
(Wong and Martin, 2010). It was therefore
suggested that muscle is the primary
target of mutant SOD1 and that toxicity
is caused by mitochondrial dysfunction,
leading to the degeneration of the neuro-
muscular junctions (NMJs—sites on
muscle fibers where nerves attach and
signal the fibers to contract), axons, and
motor neurons.
Mitochondrial damage and dysfunction
occur in human ALS patients and in SOD1
mutant transgenic mice. Furthermore,
degenerating mitochondria in the perinu-
clear region are seen in ALS transgenic
mice with either TDP43 or FUSmutations,Elsevier Inc.and VCP mutations impair mitochondrial
calcium homeostasis. Mitochondrial
abnormalities are among the earliest
signs of disease onset in transgenic
mouse models with SOD1 mutations,
and expressing mutant SOD1 confined
to mitochondria can cause the disease.
An impairment of mitochondrial fusion
and retrograde transport occurs inmutant
SOD1 transgenic mice (Magrane et al.,
2012). Misfolded SOD1 mutant protein
binds onto the cytoplasmic surface of
mitochondria, where it binds to Bcl-2,
the voltage dependent anion channel
(VDAC), and the TOM complexes, impair-
ing protein import into mitochondria.
PGC-1a functions as a molecular
rheostat, modulating the activity of genes
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Previewsinvolved in mitochondrial biogenesis
and antioxidant defenses. Of late, phar-
macologic/transcriptional activation of
the PGC-1a pathway has emerged as an
attractive approach to ameliorate mito-
chondrial dysfunction in all major neuro-
degenerative disorders. Reduced levels
of PGC-1a occur in brain tissue of
patients with Alzheimer’s disease, Parkin-
son’s disease, and Huntington’s disease
(HD). Increased expression of PGC-1a
reduces Ab plaques in vitro, improves
survival of transgenic mouse models of
ALS, and prevents atrophy of striatal
neurons in transgenic mouse models
of HD. Liang et al. (2011) showed an
age-dependent decrease in PGC-1a in
SOD1-G93A mice. Moreover, they
showed that increased expression of
PGC-1a slowed the progression of ALS,
moderately extended life span, improved
motor performance, and decreased
motor neuron death (Liang et al., 2011).
The Pasinetti lab also showed that
PGC-1a overexpression, using a neuron-
specific enolase promoter, significantly
improves motor function and survival of
SOD1-G93A mice (Zhao et al., 2011).
PGC-1a improves muscle function by
activation ofmitochondrial biogenesis, re-
sulting in more type I oxidative muscle
fibers, which are rich in mitochondria, as
well as enhancing the number of acetyl-
choline receptors at the NMJs. Da Cruz
and colleagues crossed the G37R SOD1
mutant ALS mice to transgenic mice,
which have an 8-fold increase in PGC-1a
selectively expressed in muscle by using
a muscle creatine kinase promoter (Lin
et al., 2002; Da Cruz et al., 2012).
The downstream mitochondrial genes
controlled by PGC-1a were increased,
and therewas an increase in acetylcholine
receptor clustering, which is expected
to enhance NMJs and neuromuscular
transmission. There was increased mito-
chondrial biogenesis, and the total area
of mitochondria per myofiber was sig-
nificantly increased by 3- to 4-fold, and
fine limb muscles showed increased
resistance to fatigue (Figure 1B).
These mice consistently showed a
significant increase in running perfor-
mance on a closed running wheel. At
presymptomatic stages, the muscles
showed no morphologic differences;however, at symptomatic ages, when the
fiber size and distribution of gastrocne-
mius muscle was decreased sharply in
the SOD1 G37R mice, the expression of
PGC-1a prevented muscle atrophy. Even
at end stage, muscle atrophy was signifi-
cantly reduced. The percentage of dener-
vated NMJs, however, was unaffected,
and there was no effect on numbers of
a-motor neurons, and on astroglial and
microglial activation. These findings
show that the disease is not a conse-
quence of a dying back of axons following
damage to NMJs in muscle. This finding
differs from the findings of Wong and
Martin, who observed that expression of
mutant SOD1—confined to muscle using
a skeletal muscle actin promoter—lead
to NMJ abnormalities, distal axonopathy,
and motor neuron degeneration (Wong
andMartin, 2010). They found that overex-
pression of bothwild-type aswell asG37R
and G93A mutant SOD1 were equally
toxic to motor neurons, a curious result.
The authors took care to exclude expres-
sion of the mutant SOD1 outside muscle,
withwestern blots and immunocytochem-
istry, but did not show absence of mutant
SOD1 mRNA in tissue or motor neurons.
The preponderance of evidence favors
the conclusion from the Da Cruz et al.
(2012) study, which shows that muscle
is not a primary target for mutant
SOD1 toxicity and that improving muscle
function alone is not sufficient to delay
the disease onset and to increase survival,
although it produces symptomatic bene-
fits throughout the course of the illness.
Where does this leave us? Increasing
PGC-1a expression levels appears to
be worthwhile as a palliative treatment
to maintain strength and mobility. Two
pharmacologic approaches to increase
PGC-1a are to treat with fibrates or
thioglitazones. Fibrates are predomi-
nantly PPARa activators, which have
been used to treat hyperlipidemia.
Bezafibrate exerts beneficial effects in
a mouse model of mitochondrial myop-
athy (Wenz et al., 2008). We showed
that bezafibrate activates PGC-1a,
increases numbers of mitochondria, pro-
duces neuroprotective effects, improves
muscle pathology, and extends survival
in a transgenic mouse model of HD
(Johri et al., 2012).Cell MetabolisPharmacologic approaches increasing
PGC-1a in both neurons and muscle
may, therefore, improve survival. The
importance of mitochondrial dysfunction
in the pathogenesis of ALS was greatly
strengthened by a recent phase 2 clinical
trial in ALS patients with dexpramipexole,
which localizes to mitochondria where it
exerts antioxidant effects (Cudkowicz
et al., 2011). It produced dose-dependent
improvement on the ALS functional rating
scale and increased survival. This finding,
if confirmed in an ongoing phase 3 clinical
trial, will be amajor advance in developing
neuroprotective drugs for the treatment of
ALS and will place mitochondria at the
forefront of the illness.
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